Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

What is claimed is: 
     
         1 . A method for producing an engineered T cell, comprising transducing a T cell with a T cell receptor (TCR) that binds a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49) in a complex with a MHC class I molecule. 
     
     
         2 . The method of  claim 1 , wherein the MHC class I molecule is HLA-A*0201. 
     
     
         3 . The method of  claim 1 , wherein the T cell is an autologous T cell. 
     
     
         4 . The method of  claim 1 , wherein the T cell is an allogenic T cell. 
     
     
         5 . The method of  claim 1 , wherein the T cell is a CD8+ T cell. 
     
     
         6 . The method of  claim 1 , wherein the T cell is a CD4+ T cell. 
     
     
         7 . The method of  claim 1 , wherein the T cell is a gamma/delta T cell. 
     
     
         8 . The method of  claim 1 , wherein the T cell is a cytotoxic T cell. 
     
     
         9 . The method of  claim 1 , wherein the TCR is an alpha/beta TCR. 
     
     
         10 . A pharmaceutical composition comprising the engineered T cells produced by the method of  claim 1 . 
     
     
         11 . The pharmaceutical composition of  claim 10 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-1. 
     
     
         13 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-2. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-4. 
     
     
         15 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-7. 
     
     
         16 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-12. 
     
     
         17 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-13. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-15. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-21. 
     
     
         20 . The pharmaceutical composition of  claim 11 , wherein the adjuvant is IL-23.